Dianthus Therapeutics EVP, CFO & Cbo Ryan Savitz Sells $11.2M of Stock
Ryan Savitz, EVP, CFO & Cbo, sold 124,042 shares of Dianthus Therapeutics, Inc. at $85.16 to $91.59 a share (average $90.52) in 9 transactions, worth $11.2M in total between Nov 9, 2026 and Nov 12, 2026. Shares held after the trade: 0 (-100.0%).
Dianthus Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing product candidates such as claseprubart, DNTH212, and DNTH312. As of November 2, 2026, the company reported 56,312,712 shares of common stock outstanding and is classified as a non-accelerated filer and smaller reporting company.
Dianthus Therapeutics reported Q3 2026 financial results and provided a clinical pipeline update, highlighting a cash position of approximately $1.2 billion. The company remains on track for Phase 2 MoMeNtum trial results in MMN in December 2026 and expects its current cash runway to fund operations into 2030.
“The Dianthus team continues to execute on our strategy to build a best-in-disease neuromuscular franchise with claseprubart across gMG, CIDP, and MMN, while advancing an exciting pipeline of potentially best-in-disease bifunctional fusion proteins with DNTH212 and DNTH312.”
Marino Garcia, Chief Executive Officer of Dianthus Therapeutics
Dianthus Therapeutics CAO Edward Carr Sells $2.03M of Stock
Edward Carr, CAO, sold 20,000 shares of Dianthus Therapeutics, Inc. at $100.43 to $104.39 a share (average $101.38) in 5 transactions, worth $2.03M in total on Sep 17, 2026. Shares held after the trade: 0 (-100.0%).